Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-427: Pembrolizumab in advanced RCC
NCT02853344Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Sep 2016
- Primary completion
- Feb 2021
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
01
Overview
Phase 2, open-label trial of pembrolizumab in renal cell carcinoma (RCC) (2 cohorts), sponsored by Merck & Co. Primary endpoint: Objective Response Rate at 52 months. Started Sep 2016; status: completed.
02
Drugs
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT02853344.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02853344.